Ropes & Gray advised Vor Bio in an amendment to its existing agreement with China biotechnology company RemeGen for its next-generation autoimmune drug, RC298, in a deal worth up to $356 million that was announced on November 12.
Under the amended agreement, Vor Bio will receive an exclusive license to develop and commercialize RC298 outside Greater China in exchange for upfront payment of $56 million and RemeGen is eligible to receive up to $300 million in development milestones. The upfront payment comprises $10 million in cash plus pre-funded warrants for 2.3 million shares of Vor Bio common stock, implying a total equity value of about $46 million. The existing collaboration's sales milestone and royalty framework will continue to apply on an aggregated basis across all licensed products.
RemeGen will continue to lead the preclinical and Phase 1 clinical development of RC298 in China, with both companies contributing to development efforts. Following completion of the Phase 1 clinical trial, Vor will assume responsibility for subsequent clinical development, regulatory activities, and commercialization of RC298 outside of Greater China
The Ropes & Gray team was led by life sciences licensing partner Hannah England and associate Nicole Rohr and included capital markets partner Will Michener, life sciences partners Katherine Wang and Josh Oyster, health care counsel Leslie Thornton, data, privacy & cybersecurity counsel Edward Machin.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.







